|Videos|September 1, 2021

Insights into Infection Control in a New York City-Based Hospital System

Montefiore Health System has a long history of treating infectious disease, and with the current pandemic and other emerging pathogens, they remain vigilant to potential outbreaks.

New York City has traditionally served as a destination for both immigrants and international travelers. The bright lights, the attractions, and opportunities for a new life all help to bring millions of people to its doorstep every year.

With that, it can also bring pathogens, and the city’s hospitals need to be prepared for any known or unidentified viruses or illnesses that appear.

From its beginnings, New York City-based Montefiore Health System has had a legacy of treating infectious disease. The first hospital opened in 1884, and cared for patients with tuberculosis and other chronic illnesses. And in 2020, the Montefiore Moses division became one of the first designated COVID centers, and the first to achieve in-house COVID-19 testing in New York City using the polymerase chain reaction.

Today, the health system consists of 15 hospitals and a primary and specialty care network of more than 180 locations across Westchester County, the lower Hudson Valley, and the Bronx. The health system includes the Montefiore Medical Center (Moses Division), which is an academic medical center and the primary teaching hospital of the Albert Einstein College of Medicine in the Bronx borough of New York City.

It was the rise of Ebola in 2013 that really helped Montefiore focus their attention to the possibility of treating infectious disease outbreaks, according to Priya Nori, MD, director, Antimicrobial Stewardship, Montefiore Health System and associate professor, Medicine & Orthopedic Surgery, Albert Einstein College of Medicine, program director of the infectious diseases fellowship program.

“Our hospital was one of the designated treatment locations within New York State," Nori said in speaking about their experience with Ebola. “We had to quickly stand-up a special unit…and train a cadre of nurses, providers, physicians, and people willing to take care of a patient with a highly transmissible illness.”

The Montefiore staff who were involved in the Ebola planning were able to pivot and transition to treating patients with COVID-19 when the pandemic hit New York City in the spring of 2020.

Although COVID-19 remains of paramount importance, Montefiore remains diligent to the possibility of other pathogens, including Candida auris. 

Contagion spoke with Nori recently about infection prevention protocols at Montefiore, the challenges of treating and eradicating Candida auris, and what other precautions they take to avoid potential outbreaks.


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.